基于Ad5/35平台的战略,开发针对新兴变种的广泛有效的多价值COVID-19疫苗
Soojeong Chang1, Kwang-Soo Shin1, Bongju Park1
1Research & Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.
概括
针对SARS-CoV-2 Omicron亚型的新型多价值疫苗显示了增强的中和性. 这些更新的COVID-19疫苗为当前和新兴变种提供了更广泛的保护,降低了感染风险.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) Omicron变种对现有的COVID-19疫苗疗效构成威胁.
- 多样化的Omicron亚系的出现需要更新的疫苗策略来打击突破和再感染.
研究的目的:
- 开发和评估针对SARS-CoV-2 Omicron亚型的多价值疫苗.
- 评估基于新型双价和三价腺病毒载体疫苗的免疫性和交叉中和能力.
主要方法:
- 开发双价 (BA.5/BA.2.75) 和三价 (XBB/BN.1/BQ.1.1,XBB.1.5/BN.1/BQ.1.1) 非复制性重组腺病毒载体疫苗.
- 在小鼠和模型中比较单价与多价疫苗诱导的免疫反应和交叉中和活性.
主要成果:
- 与单价疫苗相比,多价疫苗的交叉中和性得到改善.
- 在BA.5/BA.2.75双价和XBB/BN.1/BQ.1.1,XBB.1.5/BN.1/BQ.1.1三价疫苗显示增强的免疫反应.
- 开发的疫苗有效地产生了针对广泛的SARS-CoV-2变种的中和抗体.
结论:
- 多价值腺病毒载体疫苗有效增强免疫力,对循环中的Omicron亚型进行免疫.
- 这些更新的疫苗提供了针对不同SARS-CoV-2变异的广泛中和,为未来的COVID-19控制提供了有前途的战略.
更多相关视频
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
08:14Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting
Published on: October 26, 2018
8.4K
相关概念视频
01:29Immune Response Against Viral Pathogens
782
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
782
01:22Development of Immunocompetence
307
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
307
01:51Vaccinations
44.5K
Overview
44.5K
01:28Diversity of Antigen Receptors
588
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
588
01:26Antigens Involved in Adaptive Immunity
492
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
492
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K